| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G/A |
| 16 Nov 2026 | SCHEDULE 13G/A |
| 16 Nov 2026 |
8-K: Regulation FD Disclosure
(Former name or former address, if changed since last report.) |
| 16 Nov 2026 | SCHEDULE 13G/A |
| 13 Nov 2026 | QUARTERLY REPORT |
| 06 Nov 2026 | SCHEDULE 13G/A |
| 16 Sep 2026 | 25-NSE |
| 16 Sep 2026 |
8-K: Other Events
The warrants of Pasithea Therapeutics Corp. (the “Company”) to purchase shares of the Company's common stock, which trade on The Nasdaq Capital Market (“Nasdaq”) under the symbol “KTTAW” (the “Warrants”), will expire on September 17, 202... |
| 09 Sep 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On September 9, 2026, the Company held its Annual Meeting. The stockholders of the Company acted upon the following three proposals at the Annual Meeting: (1) the election of two Class III directors; (2) the ratification of the appointme... |
| 21 Aug 2026 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
As previously reported, on February 20, 2026, Pasithea Therapeutics Corp. (the “Company”) received a letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon th... |
| 14 Aug 2026 | QUARTERLY REPORT |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 07 Aug 2026 | FORM ARS |
| 07 Aug 2026 | Proxy statement: annual meeting on September 9, 2026 |
| 31 Jul 2026 | SCHEDULE 13G/A |
| 29 Jul 2026 | PRELIMINARY PROXY STATEMENT |
| 01 Jul 2026 | SCHEDULE 13G/A |
| 23 Jun 2026 | SCHEDULE 13G |
| 22 Jun 2026 |
Form 4: Coastlands Capital Lp, 10% owner
Bought 100,000 shares ($53K) |
| 15 May 2026 | QUARTERLY REPORT |
Loading...